Fecal Microbiota Transplantation for Health Improvement (TFM3)

NCT ID: NCT04011943

Last Updated: 2019-07-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-21

Study Completion Date

2020-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Search for mechanisms of the effect of fecal transplantation on a healthy organism and various nosological forms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives of the study:

1. To select donors of fecal samples for carrying out the procedure of fecal transplantation of microbiota to patients with various nosological forms.
2. To select healthy volunteers for autologous and heterologous transfusion of feces and a group of placebo-control.
3. Create a bank of fecal samples of healthy donors;
4. Conduct a procedure for fecal microbiota transplantation for a sample of patients and healthy volunteers;
5. Analyze the efficacy of therapy with TFM on the sample of patients;
6. Analyze the effect of autologous, heterologous TFM and placebo on healthy volunteers;
7. Analyze long-term effects in patients within 6 months after the TPM.

The study is expected to include 50 patients, 35 healthy volunteers and healthy feces donors The study is scheduled to begin in May 2018, the supposed completion of the study is December 2020

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis Irritable Bowel Syndrome Crohn Disease Irritable Bowel

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

In total, 85 participants must be registered. 35 are healthy volunteers. Of these volunteers, 15 will receive autologous transplantation of fecal microbiota, 10 will receive both autologous and heterologous transplantation and 10 volunteers form a placebo-controlled group.

50 participants will form a treatment group.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with bowel diseases

Treatment by transplantation of fecal microbiota

Group Type EXPERIMENTAL

Fecal Microbiota Transplantation

Intervention Type OTHER

Fecal Microbiota Transplantation

autologous transplantation of fecal microbiota - healthy

Healthy volunteers will receive autologous transplantation of fecal microbiota (capsules)

Group Type EXPERIMENTAL

Fecal Microbiota Transplantation

Intervention Type OTHER

Fecal Microbiota Transplantation

Both autologous and heterologous transplantation - healthy

Healthy volunteers will receive both autologous and heterologous transplantation (capsules)

Group Type EXPERIMENTAL

Fecal Microbiota Transplantation

Intervention Type OTHER

Fecal Microbiota Transplantation

placebo capsules - healthy

Healthy volunteers will receive placebo capsules

Group Type PLACEBO_COMPARATOR

Fecal Microbiota Transplantation

Intervention Type OTHER

Fecal Microbiota Transplantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fecal Microbiota Transplantation

Fecal Microbiota Transplantation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* the age of patients - from 18 to 75 years, both sexes;
* Patients with:

* antibiotic-associated colitis,
* inflammatory bowel diseases (ulcerative colitis, Crohn's disease),
* diseases caused by C. difficile infection,
* a syndrome of impaired intestinal absorption,
* irritable bowel syndrome,
* celiac disease (severe form),
* metabolic syndrome, including diabetes mellitus type II,
* Atopic dermatitis with damage to the mucous membrane of the colon,
* hepatitis of various etiologies,
* cirrhosis of the liver of various etiologies
* pancreatitis of various etiologies,
* Absence of contraindications to gastroscopy
* informed consent of the patient for the transplant procedure

Exclusion Criteria

* the presence of a concomitant chronic infectious or neoplastic disease in the patient
* Patients with a proven allergy to foods not excluded from the donor's diet
* absence of the patient for one or more intermediate stages of the examination.
* informed refusal to continue therapy
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Federal Research and Clinical Center of Physical-Chemical Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elena Ilina, MD

Role: PRINCIPAL_INVESTIGATOR

FRCC PCM

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

FRCC PCM

Moscow, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TFM3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fecal Microbiota Transplantation for IBS
NCT05776914 RECRUITING PHASE2